NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0315764/Prostate-Cancer-Drug-Futures.html
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED
Espicom's Prostate Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.
24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your license period
Related news
Espicom's research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.
The prostate cancer (PC) market is on the verge of considerable change....
....with the imminent arrival of new targeted therapies that will prolong patient survival. PC is the second leading cause of new cancer cases in men worldwide and the sixth leading cause of cancer death in men. In the US, over two million men currently suffer with PC and it is estimated that there were 192,311 new cases and 29,698 deaths due to the disease in 2008. There have been dramatic improvements in PC survival over the last 25 years, mainly due to a combination of earlier diagnosis and improvements in treatments, although rates vary between countries
The PC market was estimated to be worth US$5.2 billion in 2008; it is one of the larger segments of the oncology market, alongside breast, non-small cell lung and colorectal cancers. The market is currently driven by the use of hormonal therapies, which are prescribed mainly for advanced hormone-dependent PC. However, the market dynamics will change considerably over the next six years as patents expire and generic competition intensifies. Research into new therapies is extremely active and new agents with novel modes of action are being evaluated.
NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER
This all new web service from Espicom, Prostate Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.
WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...
Track the drug's progress and stay abreast of developments
Understand the drug's novelty and mode of action
Evaluate the strength of the company developing/producing the drug
Review opportunities and challenges with Espicom's unique 5-point competitive assessment
Know the launch timeframe for new products or indications
Be aware of promising mid-stage development candidates
Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS
For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…
Novelty/rationale for mechanism of action
Current status
Proof of concept/clinical data
Development risks
Company expertise
Competition within the market-place
Sales forecast (for key late-stage and launched products)
Competitor ratio analysis score
Clinical trial results
OVER 45 PROSTATE DRUGS INCLUDE:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.
Approved
Bicalutamide
Cabazitaxel
Degarelix
Docetaxel
Goserelin
Leuprorelin
Mitoxantrone
Paclitaxel
Sipuleucel-T
Filed
Dutasteride
Phase III
Abiraterone acetate
Aflibercept
Dasatinib
Ipilimumab
Radium-223
ZD4054
Phase II
AT-101
Bortezomib
Cixutumumab
E75 GM-CSF adjuvant vaccine
Enzastaurin
Figitumumab
Ixabepilone
OGX-011
OnyVax-P
PROSTVAC
Ramucirumab
Sagopilone
Vadimezan
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS
Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years' of archive material.
Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.
With Espicom's Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.
BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!
4D Research is Espicom's tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom's leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.
Table of Contents
OVERVIEW .... 1
PHASE I... 3
AE37 . 3
Mode of Action .. 3
Current Status ... 3
Proof of Concept/Clinical Data ... 3
Development Risks . 5
Company Expertise . 5
Competition within the Market-place 5
Competitor Ratio Analysis 5
ASP0265 . 6
Current Status ... 6
SAR109659 .... 7
Mode of Action .. 7
Current Status ... 7
Proof of Concept/Clinical Data ... 7
Development Risks . 8
Company Expertise . 8
Competition within the Market-place 8
Competitor Ratio Analysis 9
Clinical Trial Results .... 9
PHASE I/II .. 11
BORTEZOMIB ... 11
Mode of Action 11
Current Status .11
Proof of Concept/Clinical Data .12
Development Risks 13
Company Expertise 13
Competition within the Market-place ....13
Data Exclusivity .....14
Patent Expiry ...15
Generic Competition ....15
Competitor Ratio Analysis ....15
Forecast ...16
Clinical Trial Results ....17
PHASE II ..... 20
AT-101 .. 20
Mode of Action 20
Current Status .21
Proof of Concept ...21
Development Risks 21
Company Expertise 21
Competition within the Market-place ....22
Competitor Ratio Analysis ....22
Forecast ...22
CIXUTUMUMAB 23
Mode of Action 23
Current Status .23
Proof of Concept/Clinical Data .24
Development Risks 24
Company Expertise 24
Competition within the Market-place ....24
Competitor Ratio Analysis ....25
CUSTIRSEN SODIUM ... 26
Mode of Action 26
Current Status .26
Proof of Concept/Clinical Data .26
Development Risks 27
Company Expertise 27
Competition within the Market-place ....28
Competitor Ratio Analysis..28
DEGARELIX 29
Mode of Action 29
Current Status .29
Proof of Concept ...29
Development Risks 29
Company Expertise 30
Competition Within the Market-place ...30
Competitor Ratio Analysis ....30
Forecast ...31
DOVITINIB ... 32
Mode of Action 32
Current Status .32
Proof of Concept/Clinical Data .33
Development Risks 33
Company Expertise 33
E75 GM-CSF ADJUVANT VACCINE ..... 34
Mode of Action 34
Current Status .34
Proof of Concept/Clinical Data .34
Development Risks 35
Company Expertise 35
Competition Within the Market-place ...35
Competitor Ratio Analysis ....36
Forecast ...36
ENZASTAURIN.. 37
Mode of Action 37
Current Status .37
Proof of Concept/Clinical Data .37
Development Risks 38
Company Expertise 38
Competition within the Market-place ....38
Competitor Ratio Analysis ....39
Forecast ...39
Clinical Trial Results ..40
ERBULIN ..... 41
Clinical Trial Results ....41
FIGITUMUMAB .. 42
Mode of Action 42
Current Status .42
Proof of Concept ...42
Development Risks 43
Company Expertise 43
Competition Within the Market-place ...43
Competitor Ratio Analysis ....44
Clinical Trial Results ..45
IXABEPILONE ... 46
Mode of Action 46
Current Status .46
Proof of Concept/Clinical Data .47
Development Risks 47
Company Expertise 48
Competition within the Market-place ....48
Competitor Ratio Analysis ....48
Forecast ...49
Clinical Trial Results ....49
LY2181308 ... 52
Mode of Action 52
Current Status .52
Proof of Concept/Clinical Data .52
ONYVAX-P .. 53
Mode of Action 53
Current Status .53
Proof of Concept ...53
Development Risks 53
Company Expertise 53
Competition within the Market-place ....54
Competitor Ratio Analysis ....54
Forecast ...54
PROSTVAC . 55
Mode of Action 55
Current Status .55
Proof of Concept ...55
Development Risks 55
Company Expertise 56
Competition within the Market-place ....56
Competitor Ratio Analysis ....56
Forecast ...56
RAMUCIRUMAB 57
Mode of Action 57
Current Status .57
Proof of Concept/Clinical Data .57
Development Risks 57
Company Expertise 58
Competition within the Market-place ....58
Competitor Ratio Analysis ....58
Forecast ...59
SAGOPILONE ... 60
Mode of Action 60
Current Status .60
Proof of Concept/Clinical Data .60
Company Expertise 60
Competition within the Market-place ....61
Competitor Ratio Analysis ....61
Clinical Trial Results ..61
TASQ .... 62
Mode of Action 62
Current Status .62
Proof of Concept ...62
Development Risks 62
Company Expertise 63
Competition within the Market-place ....63
Competitor Ratio Analysis ....63
Forecast ...63
VADIMEZAN 64
Mode of Action 64
Current Status .65
Proof of Concept/Clinical Data .65
Development Risks 65
Company Expertise 65
Competition Within the Market-place ...66
Competitor Ratio Analysis ....66
Forecast ...66
Source: Espicom. ..67
Clinical Trial Results ..67
PHASE III ... 69
ABIRATERONE ACETATE . 69
Mode of Action 69
Current Status .69
Proof of Concept ...69
Development Risks 70
Company Expertise 70
Competition within the Market-place ....70
Competitor Ratio Analysis ....71
Forecast ....71
AFLIBERCEPT .. 72
Mode of Action 72
Current Status .72
Proof of Concept/Clinical Data .72
Development Risks 73
Company Expertise 73
Competition within the Market-place ....74
Competitor Ratio Analysis ....75
Forecast ...75
Clinical Trial Results ..77
DASATINIB .. 79
Mode of Action 79
Current Status .79
Proof of Concept/Clinical Data .80
Development Risks 80
Company Expertise 81
Competition within the Market-place ....81
Competitor Ratio Analysis ....82
Forecast ...82
Clinical Trial Results ..83
DUTASTERIDE .. 85
Mode of Action 85
Sales ...85
Current Status .85
Proof of Concept ...86
Development Risks 86
Company Expertise 86
Competition within the Market-place ....86
Competitor Ratio Analysis ....87
Forecast ....87
Clinical Trial Results ....87
GVAX .... 88
Clinical Trial Results ....88
Monotherapy ...88
Combination with Ipilimumab ...89
IPILIMUMAB 90
Mode of Action 90
Current Status .91
Proof of Concept/Clinical Data .91
Development Risks 92
Company Expertise 92
Competition within the Market-place ....93
Competitor Ratio Analysis ....93
Forecast ...94
Clinical Trial Results ..95
MDV3100 ..... 98
Mode of Action 98
Current Status .98
Proof of Concept ...98
Development Risks 98
Company Expertise 99
Competition within the Market-place ....99
Competitor Ratio Analysis ....99
Forecast .100
PICOPLATIN ... 101
Mode of Action ....101
Current Status .....101
Proof of Concept/Clinical Data .....101
Development Risks ....102
Company Expertise ....102
Competition within the Market-place ..103
Patent Expiry .103
Competitor Ratio Analysis ..104
RADIUM-223 .... 105
Mode of Action ....105
Current Status .....105
Clinical Trial Results ..105
SUNITINIB MALATE ... 107
Mode of Action ....107
Current Status .....108
Proof of Concept/Clinical Data .....108
Development Risks ....109
Company Expertise ....110
Competition within the Market-place ..110
Data Exclusivity ...111
Patent Expiry .111
Generic Competition ..112
Competitor Ratio Analysis ..112
Forecast .112
Clinical Trial Results 115
TOREMIFENE .. 117
Mode of Action ....117
Current Status .....117
Proof of Concept/Clinical Data .....117
Development Risks ....118
Company Expertise ....118
Competition within the Market-place ..119
Competitor Ratio Analysis ..119
TRABECTEDIN 120
Mode of Action ....120
Current Status .....120
Further Development .120
Clinical Trial Results ..121
ZD4054 124
Mode of Action ....124
Current Status .....124
Proof of Concept .124
Development Risks ....124
Company Expertise ....124
Competition within the Market-place ..125
Competitor Ratio Analysis ..125
Forecast .126
Clinical Trial Results 127
FILED .. 128
CABAZITAXEL 128
Mode of Action ....128
Current Status .....128
Proof of Concept .128
Development Risks ....128
Company Expertise ....129
Competition within the Market-place ..129
Competitor Ratio Analysis ..129
Forecast ..129
Clinical Trial Results 130
SATRAPLATIN 132
Mode of Action ....132
Current Status .....132
Proof of Concept .132
Development Risks ....132
Company Expertise ....132
Competitor Ratio Analysis133
Forecast .133
APPROVED 134
BICALUTAMIDE .... 134
Mode of Action ....134
Current Status .....134
Proof of Concept .135
Development Risks ....136
Company Expertise ....137
Competition within the Market-place ..137
Generic Competition ..138
Competitor Ratio Analysis ..138
Forecast .139
CYPROTERONE ACETATE .... 140
Mode of Action ....140
Current Status .....140
DOCETAXEL ... 141
Mode of Action ....141
Sales .141
Current Status .....141
Proof of Concept .144
Development Risks ....149
Company Expertise ....150
Competition within the Market-place ..150
Competitor Ratio Analysis ..151
Forecast .152
Clinical Trial Results ..153
GOSERELIN .... 155
Mode of Action ....155
Current Status .....155
Proof of Concept/Clinical Data .....157
Development Risks ....158
Company Expertise ....158
Competition Within the Market-place .159
Patent Expiry .159
Generic Competition ..159
Competitor Ratio Analysis ..160
Forecast .160
LEUPRORELIN 163
Mode of Action ....163
Current Status .....164
Proof of Concept/Clinical Data .....165
Development Risks ....165
Company Expertise ....166
Competition within the Market-place ..166
Patent Expiry .167
Generic Competition ..167
Competitor Ratio Analysis ..167
Forecast ..168
MITOXANTRONE .. 169
Mode of Action ....169
Current Status .....169
Proof of Concept/Clinical Data .....169
Development Risks ....170
Company Expertise ....170
Competition within the Market-place ..170
Patent Expiry .170
Generic Competition ..170
Clinical Trial Results 171
SIPULEUCEL-T ..... 172
Mode of Action ....172
Current Status .....173
Proof of Concept/Clinical Data .....174
Development Risks ....175
Company Expertise ....175
Competition Within the Market-place .176
Competitor Ratio Analysis ..176
Forecast .176
Clinical Trial Results 177
WITHDRAWN .. 179
BEVACIZUMAB ..... 179
Mode of Action ....179
Current Status .....180
Proof of Concept/Clinical Data .....183
Development Risks ....186
Company Expertise ....187
Competition within the Market-place ..187
Competitor Ratio Analysis189
Forecast ..189
Clinical Trial Results ..194
SARACATINIB 198
Mode of Action ....198
METHODOLOGY ... 199
To order this report:
Biotechnology Industry: Prostate Cancer Drug Futures
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article